MissionIR Articles
-
India Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer’s Symptoms
In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the…
-
MissionIRNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Releases Financial Report, Corporate Update for Q3
India Globalization Capital (NYSE American: IGC) (dba IGC Inc.) is reporting on its financial and corporate performance for the third fiscal quarter 2023. Highlights of the report include a focus on the company’s phase 2…
-
MissionIRNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) to Be Featured in Radius Research Webinar
India Globalization Capital (NYSE American: IGC) today announced that its CEO Ram Mukunda and PFO Claudia Grimaldi will be featured in an investor webinar hosted by Radius Research. Beginning at 12:30 p.m. ET on Friday,…
-
MissionIRNewsBreaks – India Globalization Capital Inc. (NYSE American: IGC) Set to Begin IGC-AD1 Phase 2 Trials at Sites Throughout Canada
India Globalization Capital (NYSE American: IGC) today announced its receipt of a no objection letter from Health Canada for approval of its “Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial of the Safety and Efficacy of…
-
India Globalization Capital, Inc. (NYSE: IGC) Anticipates Filing Patents for Portfolio of Drug Candidates in 2018-2019
Included are drugs formulated to treat Alzheimer’s, Parkinson’s, eating disorders and seizures IGC already has seven provisional filings for phytocannabinoid-based combination therapies Company also has in its pipeline combination therapy drug candidates for the treatment…
-
MissionIRNewsBreaks – India Globalization Capital, Inc.’s (NYSE: IGC) Cannabis-based Eating Disorder Treatment Anticipated for PCT Filing in February
India Globalization Capital (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, has recently developed IGC-506 for the treatment of multiple types of eating disorders in humans, as well…
-
India Globalization Capital, Inc. (NYSE: IGC) Targets February 2018 International Patent Filing for Eating Disorder Drug
Filing for IGC-506 anticipated to be completed in the U.S. in 2019, expanding the company’s patent portfolio; company is looking at pre-clinical trials for three of its combination drugs, possibly creating enhanced valuation IGC has…
-
MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Looks to Blockchain Technology as Possible Solution for Issues Facing Cannabis Industry
India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced plans to leverage its existing team of technology and health care experts in…
-
MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Adjourns Voting for Proposals Three and Four from Annual Meeting of Shareholders
India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that it has adjourned the voting for proposals three and four from its…
-
MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Issues Update on Efforts to Roll Out Alzheimer’s Product Hyalolex
India Globalization Capital (NYSE: IGC) today provided investors and interested parties an update on its efforts to launch its principle product for relieving the anxiety, sleep disorders and brain afflictions associated with Alzheimer’s Disease via…
-
MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Launches Pharmaceutical Cannabinoid Pipeline Websites
India Globalization Capital (NYSE American: IGC) this morning announced the launching of two new websites (www.IGCPharma.com and www.Hyalolex.com) to detail its initiatives, development timeline and pipeline of pharmaceutical cannabinoids for use in treatment of the…
-
MissionIRNewsBreaks – India Globalization Capital, Inc.’s (NYSE: IGC) Future Business Strategy
India Globalization Capital (NYSE American: IGC) is strategizing the marketing of its products and select target markets for continued growth. A recent article highlights next year’s and future year’s prospects and IGC plans, stating, “[IGC]…
-
India Globalization Capital, Inc. (NYSE: IGC) Enters MOU for Distribution in Germany, Plans to Commercialize Liquid Formulation of Hyalolex
IGC is scheduled to market a liquid formulation of its drug, IGC-AD1 (Hyalolex), in 2018; company is eyeing markets in Germany, Canada and U.S. states where licensed medical cannabis has been legalized IGC is exclusive…
-
MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Reports Q2 2018 Financial Results
India Globalization Capital (NYSE American: IGC) today reported financial results for the second quarter ended September 30, 2017, as well as an overview of recent operational highlights. The company’s legacy division which consists of rental…
-
MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Releases Results of Annual Shareholders Meeting
India Globalization Capital, Inc. (NYSE American: IGC) yesterday announced that during its 2016-2017 Annual Meeting of Shareholders on November 8, 2017, voting on Proposals Three and Four was adjourned to November 22, 2017 at 11:00…
-
MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Regains Listing Compliance
India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning announced that it has regained NYSE American listing compliance. The company received a letter…
-
MissionIRNewsBreaks – India Globalization Capital (NYSE: IGC) Avoids Regulatory Costs through Cannabis-based Drug Candidates
India Globalization Capital (NYSE AMERICAN: IGC) is developing a portfolio of products using cannabis-based “combination therapies” for the treatment of various life-altering conditions. The company is employing a distinctive strategy to bring these drug candidates…
-
India Globalization Capital, Inc. (NYSE: IGC) Targets Multiple Health Concerns with Cannabis-based Therapies
6 patents filed for pain management, eating disorders and epilepsy Additional patents underway for PTSD, depression, Alzheimer’s and Parkinson’s disease Revenue potential of each cannabis-based therapy could fetch between $100 million to $500 million India…
-
MissionIRNewsBreaks – India Globalization Capital (NYSE: IGC) Aims to Fast-Track Release of Hyalolex in Recreational Cannabis States
As a first mover in the cannabis-based combination therapy space, India Globalization Capital (NYSE AMERICAN: IGC) is preparing for the launch of its breakthrough treatment aimed at reducing beta-amyloid building up in Alzheimer’s patients, Hyalolex.…
-
India Globalization Capital, Inc. (NYSE: IGC) Could Release Potential Blockbuster Alzheimer’s Treatment in Early 2018
On the verge of releasing potential Cannabis-based blockbuster Alzheimer’s treatment Company is able to hugely accelerate release of this treatment in recreational cannabis states Market potential for drugs to treat and prevent Alzheimer’s is in…
Search Articles
Latest Articles
- MissionIRNewsBreaks – Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Marks Pivotal Moment on Path to 2026 Rare Earth Oxide Production
- PowerBank Corporation (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: 103) Marks Bold Entry Into the Growing Battery Storage Market with 4.99 MW BESS in Ontario
- Soligenix Inc. (NASDAQ: SNGX) Working to Advance Heat-Stable Ricin Vaccine with Promising Efficacy
- New Pacific Metals Corp. (NYSE American: NEWP) (TSX: NUAG) Eyes Bolivia’s Untapped Silver Potential Amid Global Supply Gaps
- MissionIRNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial